Follow us:Follow Us on Twitter Like Us on Facebook Follow Us on Google+ Watch videos on our Youtube channel
Local recurrence after mastectomy in patients with T3pN0 breast carcinoma treated without postoperative radiation therapy. Mignano JE, Gage I, Piantadosi S, Ye X, Henderson G, Dooley WC. Am J Clin Oncol 2007; 30(5):466-72.
Prediction of Lymph Node Metastasis of Breast Cancer by Integrity of Free Circulating DNA in Serum. Umetani N, Hiramatsu S, Giuliano A, Amersi F , Nakagawa T, Hoon D. Journal of Clinical Oncology, 2006; 24 (26):4270-6.
Update on Aromatase Inhibitors in Breast Cancer. Gould R, Garcia A. Current opinion in Obstetrics & Gynecology. February 2006; 18(1):41-46,
Molecular Assessment of Sentinel Lymph Nodes in Breast Cancer. Radioguided Surgery: A comprehensive team approach. Edited by Giuliano and Mariano, 2008. Amersi F, Giuliano AE, Hoon DSB.
The benefits and limitations of sentinel lymph node biopsy in 2005. Amersi F, Hansen N. Current Treatment Options Oncology. 2006; 7(2):141-151.
O'Kelly J, Chung A, Lemp N, Chumakova K, Yin D, Wang HJ, Said J, Gui D, Miller CW, Karlan BY, Koeffler HP. Functional domains of CCN1 (Cyr61) regulate breast cancer progression. Int J Oncol. 2008;33(1):59-67.
Wakimoto N, Yin D, O'Kelly J, Haritunians T, Karlan B, Said J, Xing H, Koeffler HP. Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci, 2008;99(9):1793-7.
Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro-o M, Karlan BY, Kaufman B, Koeffler HP, Rubinek T Klotho: a tumor suppressor and a modulator of the IGF-1 pathway in human breast cancer. Oncogene, 2008, in press.
Wolf I, Leitman Y, Rubinek T, Friedman E, Karlan BY, Kaufman B. A functional variant of the tumor suppressor KLOTHO: a novel risk modifier for breast cancer among BRCA1/2 carriers. European Society for Medical Oncology, Stockholm, Sweden, September, 2008.
Schummer M, Karlan B, Karlan S, Pitteri S, Green A, Wallace E, Lowe K, Urban N. Molecular profiling of tissue transcripts from invasive breast cancers and normal controls from breast-reduction surgeries could yield novel breast markers. Fifth Meeting Era of Hope for the Department of Defence (DoD) Breast Cancer Research Program, Baltimore, Maryland, June 2008.